Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus

Hepatology

Volumn 61, Issue 4, 2015, Pages 1174-1182

  van de Ven, Nikolien ^a   Fortunak, Joe ^b   Simmons, Bryony ^a   Ford, Nathan ^c   Cooke, Graham S ^a   Khoo, Saye ^d   Hill, Andrew ^d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HOWARD UNIVERSITY   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; CREATININE; DACLATASVIR; GRAZOPREVIR; LEDIPASVIR; MK 8742; RIBAVIRIN; SOFOSBUVIR; UNCLASSIFIED DRUG; HEPATITIS C ANTIGEN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD CELL COUNT; CLINICAL CHEMISTRY; CREATININE BLOOD LEVEL; DRUG COST; DRUG DOSE; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; GENOTYPE; HEALTH CARE COST; HEPATITIS C; HUMAN; LABORATORY DIAGNOSIS; LIMIT OF DETECTION; MOLECULAR WEIGHT; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TREATMENT DURATION; VIRUS LOAD; COMMERCIAL PHENOMENA; DIAGNOSTIC TEST; ECONOMICS; GENETICS; GENOTYPING TECHNIQUE; HEPACIVIRUS;

ANTIVIRAL AGENTS; COMMERCE; DIAGNOSTIC TESTS, ROUTINE; GENOTYPING TECHNIQUES; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIGENS; HUMANS;

EID: 84925374207     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27641     Document Type: Article

References (52)

1. World Health Organisation. Hepatitis C fact sheet. Updated April 2014. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed May 10, 2014.
2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-1342.
3. Londeix P, Forette C. New treatments for hepatitis C virus: strategies for achieving universal access. Médecins du Monde. 2014. Available at: http://www.hepcoalition.org/IMG/pdf/daas_strategies_for_achieving_universal_access_en.pdf. Accessed May 10, 2014.
4. Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology 2014;60:37-45.
5. Hill A, Khoo S, Fortunak J, Simmons B, Ford N. Minimum costs for producing hepatitis C direct acting antivirals, for use in large-scale treatment access programs in developing countries. Clin Infect Dis 2014;58:928-936.
6. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis c virus infection. Hepatology 2014;60:392-420.
7. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2014 Jul 28. doi: 10.1002/hep.27259. [Epub ahead of print].
8. Médecins Sans Frontières Access Campaign. Diagnosis and treatment of hepatitis C: a technical landscape. Médecins Sans Frontières. 2014. Available at: http://www.msfaccess.org/sites/default/files/MSF_assets/HepC/Docs/HepC_Report_DxTxTech_23OCT2013.pdf. Accessed May 20, 2014.
9. Callaway E. Hepatitis C drugs not reaching poor. Nature 2014;508:295-296.
10. UNITAID. HIV medicines technology and market landscape. UNITAID and World Health Organisation. 2014. Available at: http://www.unitaid.eu/images/marketdynamics/publications/HIV-Meds-Landscape-March2014.pdf. Accessed May 17, 2014.
11. Hill A, Cooke G. Hepatitis C can be cured globally, but at what cost? Science 2014;345:141-142.
12. The Lancet. Only just the beginning of the end of hepatitis C. Lancet 2014;383:281.
13. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-221.
14. Tice JA, Ollendorf DA, Pearson SD. The comparative clinical effectiveness and value of simeprevir and sofosbuvir in the treatment of chronic hepatitis C infection. Institute for Clinical and Economic Review. 2014. Available at: http://ctaf.org/sites/default/files/assessments/CTAF_Hep_C_Apr14_final.pdf. Accessed May 20, 2014.
15. Gane EJ, Stedman CA, Hyland RH, Sorensen RD, Symonds WT, Hindes R, et al. Once daily sofosbuvir (GS-7977) plus ribavirin in patients with HCV genotypes 1, 2, and 3: The ELECTRON Trial. Paper presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 9-13, 2012, Boston, MA. Abstract 229.
16. Gane EJ, Stedman CA, Hyland RH, Ding X, Pang PS, Symonds WT, et al. ELECTRON: all-oral sofosbuvir-based 12-week regimens for the treatment of chronic HCV GT 1 infection. Paper presented at the 48th Annual Meeting of the European Association for the Study of Liver Disease (EASL), April 24-28, 2013, Amsterdam, The Netherlands. Abstract 14.
17. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-1877.
18. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. GS-7977 and ribavirin in treatment naive and treatment experienced subjects with chronic genotype 2 or 3 HCV infection. Paper presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 1-5, 2013, Washington, DC. Abstract 1085.
19. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-1887.
20. Naggie S, Sulkowski M, Lelazeri J, Fessel WJ, Mounzer K, Shuhart M, et al. Sofosbuvir plus ribavirin for HCV genotype 1-3 infection in HIV coinfected patients (PHOTON-1). Paper presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI), March 3-6, 2014, Boston, MA. Abstract 26.
21. Ruane PJ, Ain D, Meshrekey R, Riad J, Stryker R, Soliman M, et al. Sofosbuvir plus ribavirin, an interferon-free regimen, in the treatment of treatment-naïve and treatment-experienced patients with chronic genotype 4 HCV infection. Paper presented at the 49th Annual Meeting of the European Association for the Study of the Liver (EASL), April 9-13, 2014, London, UK. Abstract P1243.
22. Osinusi A, Meissner EG, Bon D, Lee YJ, Proschan M, Hermann E, et al. High efficacy of sofosbuvir in combination with weight based ribavirin for 24 weeks in difficult to treat HCV infected genotype-1 patients. Paper presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI), March 3-6, 2013, Atlanta, GA. Abstract 157-LB.
23. Lawitz E, Poordad FF, Pang PS, Hyland RH, Mo H, Symonds WT, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014;383:515-523.
24. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, An D, et al. Ledipasvir/sofosbuvir with and without ribavirin for 8 weeks compared to ledipasvir/sofosbuvir for 12 weeks in treatment naïve noncirrhotic genotype-1 HCV-infected patients: the phase 3 ION-3 study. Paper presented at the 49th Annual Meeting of the European Association for the Study of the Liver (EASL), April 9-13, 2014, London, UK. Abstract O56.
25. Mangia A, Marcellin P, Kwo P, Foster GR, Buti M, Brau N, et al. All oral fixed-dose combination sofosbuvir/ledipasvir with or without ribavirin for 12 or 24 weeks in treatment-naïve genotype 1 HCV-infected patients: the phase 3 ION-1 study. Paper presented at the 49th Annual Meeting of the European Association for the Study of the Liver (EASL), April 9-13, 2014, London, UK. Abstract O164.
26. Kohli A, Sims Z, Marti M, Nelson A, Osinusi A, Bon D, et al. Combination oral hepatitis C antiviral therapy for 6 or 12 weeks: final results of the SYNERGY trial. Paper presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI), March 3-6, 2014, Boston, MA. Abstract 27-LB.
27. Osinusi A, Townsend K, Nelson A, Kohli A, Gross C, Polis MA, et al. Use of sofosbuvir/ledipasvir fixed dose combination for treatment of HCV genotype-1 in patients coinfected with HIV. Paper presented at the 49th Annual Meeting of the European Association for the Study of the Liver (EASL), April 9-13, 2014, London, UK. Abstract O14.
28. Gane EJ, Hyland RH, An D, Pang PS, Symonds WT, Mchutchison JG, et al. Sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior sofosbuvir treatment experience. Paper presented at the 49th Annual Meeting of the European Association for the Study of the Liver (EASL), April 9-13, 2014, London, UK. Abstract O6.
29. Hezode C, Serfaty L, Vierling JM, Kugelmas M, Pearlman B, Sievert W, et al. Safety and efficacy of the all-oral regimen of MK-5172/MK-8742±ribavirin in treatment-naive, non-cirrhotic, patients with hepatitis C virus genotype 1 infection: the C-WORTHY study. Paper presented at the 49th Annual Meeting of the European Association for the Study of the Liver (EASL), April 9-13, 2014, London, UK. Abstract O10.
30. Lawitz E, Hezode C, Gane E, Tam E, Lagging M, Balart L, et al. Efficacy and safety of MK-5172 and MK-8742±ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null-response: the C-WORTHY study. Paper presented at the 49th Annual Meeting of the European Association for the Study of the Liver (EASL), April 9-13, 2014, London, UK. Abstract O61.
31. Sulkowski M, Mallolas J, Pol S, Gerstoft J, Shibolet O, Nahass R, et al. Efficacy and safety of the all-oral regimen, MK-5172/MK-8742 +/- RBV for 12 weeks in GT1 HCV/HIV co-infected patients: the C-WORTHY study. Paper presented at the 49th Annual Meeting of the European Association for the Study of the Liver (EASL), April 9-13, 2014, London, UK. Abstract O63.
32. National Health Laboratory Service. State pricing list 2012-2013. Available at: http://www.nhls.ac.za/. Accessed May 3, 2014.
33. Tedder RS, Tuke P, Wallis N, Wright M, Nicholson L, Grant PR. Therapy-induced clearance of HCV core antigen from plasma predicts an end of treatment viral response. J Viral Hepat 2013;20:65-71.
34. Coburn CA, Meinke PT, Chang W, Fandozzi CM, Graham DJ, Hu B, et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem 2013;8:1930-1940.
35. Harper S, McCauley JA, Rudd MT, Ferrara M, DiFilippo M, Crescenzi B, et al. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor. ACS Med Chem Lett 2012;3:332-336.
36. Kuethe J, Zhong YL, Yasuda N, Beutner G, Linn K, Kim M, et al. Development of a practical asymmetric synthesis of the hepatitis C virus protease inhibitor MK-5172. Org Lett 2013;15:4174-4177.
37. Link JO, Taylor JG, Xu L, Mitchell M, Guo H, Liu H, et al. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem 2014;57:2033-2046.
38. Morota K, Fujinami R, Kinukawa H, Machida T, Ohno K, Saegusa H, et al. A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis c virus core antigen. J Virol Methods 2009;157:8-14.
39. Vermehren J, Susser S, Berger A, Perner D, Pfeiffer KH, Allwin R, et al. Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1. J Clin Virol 2012;55:17-22.
40. Gupta E, Bajpai M, Choudhary A. Hepatitis C virus: screening, diagnosis, and interpretation of laboratory assays. Asian J Transfus Sci 2014;8:19-25.
41. Kesli R, Polat H, Terzi Y, Kurtoglu M, Uyar Y. Comparison of a newly developed automated and quantitative hepatitis C virus (HCV) core antigen test with the HCV RNA assay for clinical usefulness in confirming Anti-HCV results. J Clin Microbiol 2011;49:4089.
42. Ciotto M, D'Agostini C, Marrone A. Advances in the diagnosis and monitoring of hepatitis C virus infection. Gastroenterol Res 2013;6:161-170.
43. Hosseini-Moghaddam SM, Iran-Pours E, Rotstein C, Husain S, Lilly L, Renner E, et al. Hepatitis C core Ag and its clinical applicability: potential advantages and disadvantages for diagnosis and follow-up? Rev Med Virol 2012;22:156-165.
44. Miedouge M, Saune K, Kamar N, Rieu M, Rostaing L, Izopet J. Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol 2010;48:18-21.
45. Bhagani S. A hepatitis C virus core antigen assay is a cost-effective, sensitive and specific test in the detection of acute hepatitis C in HIV infection. Presented at the 3rd Joint Conference of the British HIV Association (BHIVA) and British Association for Sexual Health and HIV (BASHH), April 1-4, 2014, Liverpool, UK. Abstract O22.
46. Park Y, Lee JH, Kim BS, Kim DY, Han KH, Kim HS. New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification. J Clin Microbiol 2010;48:2253-2256.
47. Hill A, Khoo S, Simmons B, Ford N. What is the minimum cost per person to cure HCV? Poster presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 1-5, 2013, Washington, DC. Poster 1097.
48. Anilkumar GN, Rosenblum SB, Venkatraman S, Njoroge FG, Kozlowski JA. 2, 3-substituted azaindole derivatives for treating viral infections. US8404845 (patent). 2013. Available at: http://www.google.com/patents/US8404845. Accessed May 22, 2014.
49. Harper S, Liverton NJ, McCauley JA, Summa V. Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors. US8080654 (patent). 2011. Available at: http://www.google.com/patents/US8080654. Accessed May 23, 2014.
50. Gilead Sciences Inc. Form 10-K: annual report pursuant to section 13 or 15(d) of the securities exchange act of 1934. Fiscal year ending Dec 31, 2012. Page 17. 2013. Available at: http://www.sec.gov/Archives/edgar/data/882095/000088209513000015/a2012form10-k.htm. Accessed May 24, 2014.
51. New W. Rich and poor countries divided on patent treaty. Bulletin of the WHO. 2006;84:337-424.
52. Médicins Sans Frontières Access Campaign. Untangling the web of antiretroviral price reductions. Médicins Sans Frontières. 2013. Available at: www.msfaccess.org/content/untangling-web-antiretroviral-price-reductions-16th-edition. Accessed May 11, 2014.